These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 20464498)

  • 1. Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease.
    Arun P; Madhavarao CN; Moffett JR; Hamilton K; Grunberg NE; Ariyannur PS; Gahl WA; Anikster Y; Mog S; Hallows WC; Denu JM; Namboodiri AM
    J Inherit Metab Dis; 2010 Jun; 33(3):195-210. PubMed ID: 20464498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
    von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
    Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
    Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M
    J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain.
    Mathew R; Arun P; Madhavarao CN; Moffett JR; Namboodiri MA
    J Pharmacol Exp Ther; 2005 Oct; 315(1):297-303. PubMed ID: 16002461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
    Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
    Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.
    Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P
    Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease.
    McPhee SW; Francis J; Janson CG; Serikawa T; Hyland K; Ong EO; Raghavan SS; Freese A; Leone P
    Brain Res Mol Brain Res; 2005 Apr; 135(1-2):112-21. PubMed ID: 15857674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease.
    Madhavarao CN; Arun P; Moffett JR; Szucs S; Surendran S; Matalon R; Garbern J; Hristova D; Johnson A; Jiang W; Namboodiri MA
    Proc Natl Acad Sci U S A; 2005 Apr; 102(14):5221-6. PubMed ID: 15784740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canavan disease and the role of N-acetylaspartate in myelin synthesis.
    Namboodiri AM; Peethambaran A; Mathew R; Sambhu PA; Hershfield J; Moffett JR; Madhavarao CN
    Mol Cell Endocrinol; 2006 Jun; 252(1-2):216-23. PubMed ID: 16647192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glyceryl triacetate for Canavan disease: a low-dose trial in infants and evaluation of a higher dose for toxicity in the tremor rat model.
    Madhavarao CN; Arun P; Anikster Y; Mog SR; Staretz-Chacham O; Moffett JR; Grunberg NE; Gahl WA; Namboodiri AMA
    J Inherit Metab Dis; 2009 Oct; 32(5):640. PubMed ID: 19685155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase.
    Chakraborty G; Mekala P; Yahya D; Wu G; Ledeen RW
    J Neurochem; 2001 Aug; 78(4):736-45. PubMed ID: 11520894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy.
    Sohn J; Bannerman P; Guo F; Burns T; Miers L; Croteau C; Singhal NK; McDonough JA; Pleasure D
    J Neurosci; 2017 Jan; 37(2):413-421. PubMed ID: 28077719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A safety trial of high dose glyceryl triacetate for Canavan disease.
    Segel R; Anikster Y; Zevin S; Steinberg A; Gahl WA; Fisher D; Staretz-Chacham O; Zimran A; Altarescu G
    Mol Genet Metab; 2011 Jul; 103(3):203-6. PubMed ID: 21474353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelin lipid abnormalities in the aspartoacylase-deficient tremor rat.
    Wang J; Leone P; Wu G; Francis JS; Li H; Jain MR; Serikawa T; Ledeen RW
    Neurochem Res; 2009 Jan; 34(1):138-48. PubMed ID: 18478328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic acetate therapy for the treatment of traumatic brain injury.
    Arun P; Ariyannur PS; Moffett JR; Xing G; Hamilton K; Grunberg NE; Ives JA; Namboodiri AM
    J Neurotrauma; 2010 Jan; 27(1):293-8. PubMed ID: 19803785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology.
    Moffett JR; Ross B; Arun P; Madhavarao CN; Namboodiri AM
    Prog Neurobiol; 2007 Feb; 81(2):89-131. PubMed ID: 17275978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.
    Traka M; Wollmann RL; Cerda SR; Dugas J; Barres BA; Popko B
    J Neurosci; 2008 Nov; 28(45):11537-49. PubMed ID: 18987190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelin lesion in the aspartoacylase (Aspa) knockout rat, an animal model for Canavan disease.
    Takeda S; Hoshiai R; Tanaka M; Izawa T; Yamate J; Kuramoto T; Kuwamura M
    Exp Anim; 2024 Jul; 73(3):347-356. PubMed ID: 38538326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model.
    Becker I; Wang-Eckhardt L; Eckhardt M
    J Inherit Metab Dis; 2024 Mar; 47(2):230-243. PubMed ID: 38011891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspartoacylase is restricted primarily to myelin synthesizing cells in the CNS: therapeutic implications for Canavan disease.
    Kirmani BF; Jacobowitz DM; Kallarakal AT; Namboodiri MA
    Brain Res Mol Brain Res; 2002 Nov; 107(2):176-82. PubMed ID: 12487123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.